MF-300 sarcopenia program
phase 2drug program · high · Fri Dec 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Develop an oral small-molecule therapy targeting PGE-2 signaling for sarcopenia, aiming to restore tissue homeostasis and improve age-related muscle decline.
Phase 2b clinical study of MF-300; separate healthy-participant single-ascending-dose, food-effect, and multiple-ascending-dose evaluation in non-elderly and elderly adults.
Phase 2b study for sarcopenia; ClinicalTrials.gov record for single and multiple ascending dosing of MF-300 published 2024-12-20.
EPM-01 Becker muscular dystrophy program
phase 1drug program · high · Fri Jan 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Evaluate safety, early efficacy, and biomarker response of an epicatechin-based oral therapy in Becker or Becker-like muscular dystrophy.
Phase 1 open-label dose-escalation clinical trial of (+)-epicatechin/EPM-01 in Becker muscular dystrophy, with neuromuscular, safety, and biomarker endpoints.
Phase 1 clinical trial listed for Becker muscular dystrophy; related publication reported short-term biomarker and exercise-testing changes in adults with BMD.
In a seven-patient open-label BMD study, epicatechin increased markers associated with mitochondrial biogenesis and muscle regeneration, including follistatin, and improved selected exercise-testing parameters.
Friedreich's ataxia epicatechin clinical research program
phase 2research program · medium · Fri Jan 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Assess safety and potential neurological and cardiac efficacy of oral (+)-epicatechin in pediatric subjects with Friedreich's ataxia.
Phase II open-label, baseline-controlled single-center study administering oral (+)-epicatechin for 24 weeks with neurological, walking, cardiac MRI, echocardiography, electrophysiology, and biomarker endpoints.
2021 publication of Phase II open-label study results.
(+)-epicatechin was well tolerated up to 150 mg/day with no serious adverse events; cardiac structure and function improved in subsets, while primary neurological outcomes did not show statistically significant improvement.
Idiopathic pulmonary fibrosis preclinical program
preclinicaldrug program · medium
Explore oral small-molecule modulation of PGE-2 signaling to reduce fibrosis in idiopathic pulmonary fibrosis.
Preclinical efficacy research with Epirium small molecules.
Company cites preclinical efficacy data in idiopathic pulmonary fibrosis.
Preclinical efficacy data are cited, but detailed results are not included in the supplied material.
Irritable bowel disease preclinical program
preclinicaldrug program · medium
Explore oral small-molecule modulation of PGE-2 signaling to resolve inflammation and restore tissue homeostasis in irritable bowel disease.
Preclinical efficacy research with Epirium small molecules.
Company cites preclinical efficacy data in irritable bowel disease.
Preclinical efficacy data are cited, but detailed results are not included in the supplied material.
PGE-2 signaling oral small-molecule platform
exploratoryplatform · high
Develop orally bioavailable small molecules that leverage PGE-2 signaling to restore tissue homeostasis, resolve inflammation, stimulate regeneration, and reduce fibrosis across neuromuscular, inflammatory, and fibrotic diseases.
Small-molecule discovery and development platform focused on PGE-2 signaling biology.
Platform supports listed pipeline programs including MF-300 and EPM-01.
Spinal muscular atrophy preclinical program
preclinicaldrug program · medium
Explore Epirium's oral small-molecule approach for spinal muscular atrophy using tissue-homeostasis and regenerative mechanisms linked to PGE-2 signaling.
Preclinical efficacy research with Epirium small molecules.
Company cites preclinical efficacy data in spinal muscular atrophy.
Preclinical efficacy data are cited, but detailed results are not included in the supplied material.
